Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ERN1 | O75460 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.47 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2102755 | 0.82 | NPC1 (0.53) | ALDH1A1MEN1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL6513965 | 0.80 | NPC1 (0.52) | ALDH1A1MEN1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL6513971 | 0.80 | NPC1 (0.52) | ALDH1A1MEN1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL6517392 | 0.80 | NPC1 (0.52) | ALDH1A1MEN1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL29950410 | 0.78 | ALDH1A1 (0.61) | ALDH1A1MEN1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL67498 | 0.78 | ALDH1A1 (0.61) | ALDH1A1MEN1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL13066221 | 0.78 | CA1 (0.50) | ALDH1A1MEN1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL2128103 | 0.77 | ALDH1A1 (0.47) | ALDH1A1KMT2AMCL1CA12CA1 | |
| SCHEMBL2132879 | 0.77 | NQO1 (0.50) | ALDH1A1MEN1GAAKMT2AKDM4E | |
| SCHEMBL29763172 | 0.76 | NPC1 (0.61) | ALDH1A1MEN1GAAKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106841160-B | Method for rapidly detecting hypochlorous acid in cells in situ | 华东理工大学 | 2020-04-17 | — | — | CN | claimed |
| US-9006391-B2 | Method for the preparation of cyclopeptides | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2015-04-14 | — | — | US | disclosed |
| EP-2452944-B1 | DIPHENYL SULFIDE DERIVATIVES AND MEDICINES CONTAINING THEM AS ACTIVE INGREDIENT | KYORIN SEIYAKU KK (JP) | 2014-09-10 | — | — | EP | disclosed |
| US-8569270-B2 | Diphenyl sulfide derivatives and medicines containing same as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2452944-A1 | DIPHENYL SULFIDE DERIVATIVES AND MEDICINES CONTAINING SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2012-05-16 | — | — | EP | disclosed |
| US-20120101068-A1 | DIPHENYL SULFIDE DERIVATIVES AND MEDICINES CONTAINING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
| US-8163770-B2 | Benzoxathiin derivative | MSD. K. K. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163770-B2 | Benzoxathiin derivative | MSD. K. K. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163770-B2 | Benzoxathiin derivative | MSD. K. K. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2427477-A1 | METHOD FOR THE PREPARATION OF CYCLOPEPTIDES | DSM Sinochem Pharmaceuticals Netherlands B.V. (NL) | 2012-03-14 | — | — | EP | disclosed |
| US-20100168156-A1 | Novel Benzoxathiine Derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168156-A1 | Novel Benzoxathiine Derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-1944301-A1 | NOVEL BENZOXATHIIN DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1944301-A1 | NOVEL BENZOXATHIIN DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-0145494-B1 | 1,5-BENZOXATHIEPIN DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1989-11-08 | — | — | EP | disclosed |
| EP-0300088-A2 | 1,5-Benzoxathiepin derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1989-01-25 | — | — | EP | disclosed |
| US-4751316-A | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-06-14 | — | — | US | disclosed |
| US-4672064-A | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-06-09 | — | — | US | disclosed |
| EP-0145494-A2 | 1,5-Benzoxathiepin derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1985-06-19 | — | — | EP | disclosed |
| US-4308276-A | Inhibiting lipogenesis with benzoxathiincarboxamides | SHELL OIL COMPANY (US) | 1981-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168156-A1 | Novel Benzoxathiine Derivative | XDH, GPR119, BRIX1 | ALDH1A1 1579/4885MEN1 4579/4885GAA 2878/4885 |
| US-20120101068-A1 | DIPHENYL SULFIDE DERIVATIVES AND MEDICINES CONTAINING SAME AS ACTIVE INGREDIENT | S1PR3, S1PR1, S1PR2 | ALDH1A1 1665/4885MEN1 1167/4885GAA 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.